Drug Channels

OCTOBER 19, 2020

Copyright © 2006-2020 Pembroke Consulting, Inc. Channel Strategy for First Medical Product – A Look at Channel Considerations for Pharmacy vs. Other restrictions may apply. The content of Sponsored Posts does not necessarily reflect the views of Pembroke Consulting, Inc., Drug Channels, or any of its employees. d/b/a Drug Channels Institute.

Specialty Pharmacies 52

Specialty Pharmacies Science Pharmacy Licensing 52

Drug Channels

DECEMBER 1, 2020

During 2020, the COVID-19 pandemic disrupted every aspect of the pharmaceutical channel—and our lives. Pharmacy and healthcare provider markets experienced unprecedented volatility. Pharmaceutical wholesalers have maintained shipments and operational capacity. Read more » Copyright © 2006-2020 Pembroke Consulting, Inc.

Pharmacy 52

Pharmacy Vaccine Drugs Pharmaceuticals 52

Drug Channels

OCTOBER 26, 2020

You’ll hear perspectives from companies such as ADC Therapeutics, Alkermes, Amgen, Apellis Pharmaceuticals, Bristol-Myers Squibb, Cipla Therapeutics, Deloitte & Touche LLP, Eisai US, Eli Lilly & Co, IntegriChain, Intra-Cellular Therapies, MyoKardia, Paratek Pharmaceuticals and Teva Pharmaceuticals.

Government 40

Government Pharmaceuticals Science Production 40

Agency IQ

NOVEMBER 10, 2023

Services incurring fees include marketing authorization applications, variations, scientific advice, and inspections. Fees supplemental to the basic fees can be collected for authorization of additional strengths and pharmaceutical forms. literature monitoring), since national regulators charge their own fees.

Regulations 40

Regulations Pharmaceuticals Government Therapies 40

The Pharma Data

SEPTEMBER 17, 2020

This is the focus of vaccines in development and convalescent plasma therapy. Basel, 18 September 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the launch of its Elecsys® Anti-SARS-CoV-2 S antibody test for markets accepting the CE Mark. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.

Vaccine 52

Vaccine Virus Clinical Trials Immune Response 52

Drug Discovery World

FEBRUARY 15, 2023

Existing therapies have been focused on eliminating the cancer cells and/or on preventing its progression by using a combination of chemotherapy, radiotherapy, and surgical approaches. Genetically modified T cells stimulated with IL2 are now administered as cell therapy for multiple cancer cell types with beneficial results 3,4.

Research 130

Research Therapies Immune Response Clinical Trials 130

Drug Channels

MAY 22, 2023

WHAT YOU WILL LEARN As expensive specialty therapies come to dominate drug spending, pharmaceutical manufacturers are paying a growing share of patents’ out-of-pocket costs for these prescriptions. Copyright © 2006-2023 Pembroke Consulting, Inc. This event is part of The Drug Channels 2023 Video Webinar Series.

Pharmacy 97

Pharmacy Drugs Marketing Pharmaceuticals 97

Agency IQ

JUNE 9, 2023

Though some of the concepts can be applied to more complex products such as biologics and cell and gene therapies, these products are more difficult to assess as many animal species that can be used for in vivo testing of small molecule products are not suitable, as their immune systems are not comparable to humans.

FDA 40

FDA Small Molecule Science Immune Response 40

The Pharma Data

NOVEMBER 24, 2020

24, 2020– Alnylam Pharmaceuticals, Inc. Food and Drug Administration (FDA) approved Oxlumo (lumasiran) injection for subcutaneous use, the first-ever therapy available for the treatment of primary hyperoxaluria type 1 (PH1) to lower urinary oxalate levels in pediatric and adult patients. CAMBRIDGE, Mass.–(BUSINESS

FDA Approval 52

FDA Approval Treatment FDA RNA 52

Agency IQ

APRIL 12, 2024

The vote is in: The European Parliament has adopted the compromise pharmaceutical legislation This week, the European Parliament voted to adopt the compromise texts of both the revised pharmaceutical directive and regulation presented by Parliament’s health committee in March 2024. has a strong voice in the world. citizens; 2.

Pharmaceuticals 40

Pharmaceuticals Packaging Regulations Production 40

Agency IQ

JULY 28, 2023

On March 27, the FDA finalized a transition guidance document covering products that had been marketed under enforcement discretion policies during the PHE. First, by March 2021, manufacturers were expected to conclude a risk assessment of their approved or marketed products to assess the risk of nitrosamines.

FDA 40

FDA Science Biosimilars Regulations 40

Drug & Device Law

MAY 30, 2022

The plaintiffs’ causation allegations foundered in Himes because the treating physician did not believe that the claimed risks of electroconvulsive therapy were all that big of a deal, and thus did not warn about it. Bayer HealthCare Pharmaceuticals, Inc. , Wyeth Pharmaceuticals , 526 F.3d Janssen Pharmaceuticals, Inc.

Testimonials 59

Testimonials Doctors Production Laboratories 59

Drug & Device Law

JUNE 6, 2022

Bayer HealthCare Pharmaceuticals, Inc. , Wyeth Pharmaceuticals , 526 F.3d Janssen Pharmaceuticals , 2018 WL 1977258, at *12 (Mag. Teva Pharmaceuticals USA, Inc. , Novartis Pharmaceuticals Corp. , Lineberger v. Wyeth , 894 A.2d 2d 141 (Pa. Salinero also followed the recent Hubbard v. 3d 1223, 1233 (11th Cir.

Testimonials 59

Testimonials Production Pharmaceuticals Treatment 59